Key result
Percutaneous edge-to-edge mitral valve repair using the MitraClip device is an established therapy for severe, symptomatic functional and degenerative mitral regurgitation.
Why the study?
To discuss the evolution of the MitraClip device, the clinical studies supporting its use, and the concept of proportionate and disproportionate MR in patients with severe mitral regurgitation.
This review discusses the evolution, clinical evidence, and indications for percutaneous edge-to-edge mitral valve repair using the MitraClip device in severe mitral regurgitation.
Supports MitraClip for high-risk severe degenerative MR; reinforces its status as leading percutaneous option with extensive procedural data.
Percutaneous edge-to-edge mitral valve repair, using the MitraClip device for severe mitral regurgitation (MR) was first introduced in 2003. Since then, more than 100,000 cases have been performed worldwide and it remains the most established percutaneous therapy available for the treatment of severe MR. Currently, it is indicated for severe, symptomatic functional MR in patients who continue to have significant symptoms despite optimal guideline directed medical therapy, as well as in symptomatic patients with severe degenerative MR who are deemed too high risk for conventional surgical therapy in the opinion of the heart team. In this paper, we discuss the evolution of the MitraClip device, the clinical studies supporting its use as well as the important concept of proportionate and disproportionate MR.
No takes yet. Share an insight, caveat, or question.
Yeo et al. (2020) conducted a review in severe mitral regurgitation (MR). Percutaneous edge-to-edge mitral valve repair (MitraClip) was evaluated. Percutaneous edge-to-edge mitral valve repair using the MitraClip device is an established therapy for severe, symptomatic functional and degenerative mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: